Market revenue in 2023 | USD 2,621.7 million |
Market revenue in 2030 | USD 3,815.3 million |
Growth rate | 5.5% (CAGR from 2023 to 2030) |
Largest segment | Mammalian source |
Fastest growing segment | Mammalian Source |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Microbial Source, Mammalian Source, Other Source |
Key market players worldwide | WuXi Biologics (Cayman) Inc, FUJIFILM Holdings Corp, AGC Biologics, Thermo Fisher Scientific Inc, Curia, Genscript Biotech Corp Class H, Boehringer Ingelheim Pharma, Abzena, JSR Corp, Bionova Scientific |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biologics contract development market will help companies and investors design strategic landscapes.
Mammalian source was the largest segment with a revenue share of 55.85% in 2023. Horizon Databook has segmented the U.S. biologics contract development market based on microbial source, mammalian source, other source covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. market is expected to witness lucrative growth due to key factors such as increasing R&D investments and high adoption of advanced technology. Developed markets, like the U.S., still hold a major share of clinical trial activity.
The U.S spends 2.7% of their GDP on R&D, out of which the business and government sectors account for highest spending. The U.S. is a leader in pharmaceuticals, and research companies invest nearly one fifth of their revenues into R&D.
These factors boost growth of the market. According to UNESCO, there are 4,205 researchers per million inhabitants in the country. The Biologics Price Competition and Innovation Act (BPCIA) has been implemented by the FDA for a feasible licensing pathway for biological products or biosimilars.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. biologics contract development market, including forecasts for subscribers. This country databook contains high-level insights into U.S. biologics contract development market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account